Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.
Greater Than One Chief Creative Officer Ross Thomson analyzes how to avoid mistranslation and produce compelling, memorable and effective advertising.
Eli Lilly and Co. beat analysts’ estimates for second-quarter 2019 profit and raised the company’s full-year earnings forecast, as higher sales of the diabetes drugs Trulicity and Basaglar offset competition for the erectile dysfunction treatment Cialis.
The U.S. Food and Drug Administration declined to approve Aquestive Therapeutics Inc.’s erectile dysfunction treatment tadalafil and sought additional data.
Pfizer’s big-selling erectile dysfunction drug Viagra was given a green light for sale without a prescription in Britain, the first country to grant it over-the-counter status.
Argentum Pharmaceuticals announced that it reached a settlement and license agreement with Eli Lilly related to Argentum’s generic version of Cialis (tadalifil).
Eli Lilly entered into a settlement agreement with generic companies to resolve pending patent litigation regarding the Cialis (tadalafil) unit dose patent.
To build brands in this most personal of industries, healthcare marketers must first make the human connection.